AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05289622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyurethane expandable valve stent implant
Description: The baseline assessment of patients will include the admission of patients and the performance of preoperative exams (cardiological imaging for the correct selection). An estimated surgery time of 5 hours. During the entire procedure, patients will be under general anesthesia and controlled mechanical ventilation. The material collected in the laboratory will be processed, the result released and discarded. After the patient enters the operating room, hemodynamic monitoring, ECG, arterial saturation, with peripheral sensor, central venous access with double lumen catheter will be carried out; blood pressure monitoring by radial artery puncture, bladder catheter and thermometer in the nasopharynx and rectum. After preoperative preparation, patients will undergo a surgical approach by median thoracotomy and installation of the Cardiopulmonary bypass (ECC) circuit, by placing a cannula in the ascending aorta, Superior Vena Cava (SVC) and Inferior Vena Cava (IVC).
Study NCT05274932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BFR resistance exercise
Description: 4 sets (30, 15, 15, 15 reps).
Study NCT05274932 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BFR resistance exercise
Description: 4 sets (30, 15, 15, 15 reps).
Study NCT05217641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG505 MD39.3 gp151 CD4KO mRNA
Description: Administered by IM injection
Study NCT05100225 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PTP-001
Description: Allogeneic human placental tissue particulate (PTP-001) is administered as a single intra-articular injection to the target knee after resuspension with saline.
Study NCT05100225 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: The placebo control, physiological saline (0.9% sodium chloride injection, USP), is administered as an intra-articular injection to the target knee.
Study NCT05194306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perla® Cold Preservation solution
Description: Perla® must be cooled to 2° to 6 °C prior to use. The cold Preservation Solution is used to flush the isolated organ immediately before removal from the donor and/or immediately after removal from the donor. The solution is then left in the organ vasculature during hypothermic storage and transportation.
Study NCT05745142 — intervention group
Intervention type: DRUG
Intervention: Sunitinib
Description: as provided in real world practice
Study NCT05244603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ideal binary mask
Description: Speech in noise processed by ideal binary mask to reduce background noise
Study NCT04940052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib will be administered orally twice daily
Study NCT04940052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib will be administered orally once daily
Study NCT04940052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trametinib placebo
Description: Trametinib will be administered orally once daily
Study NCT04940052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dabrafenib placebo
Description: Dabrafenib placebo will be administered orally twice daily
Study NCT05732441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huange capsule
Description: Huange Capsule was orally administered (Zhejiang Kangenbe Pharmaceutical Co., Ltd., specification: 0.4g×60 tablets/bottle, GuoYaoZhunZi Z20110006). Administration method: 1.6g each time, three times a day, 40min after breakfast, lunch and dinner. The treatment course was four weeks.
Study NCT04871204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Injection
Description: 10 mg Sandostatin LAR intramuscular injection
Study NCT05682235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise AND pain neurophysiology education
Description: A program of therapeutic exercise and education in the neurophysiology of pain will be applied to the participants of the experimental group and talks on healthy habits to the placebo group participants.
Study NCT05682235 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Talk about healthy habits
Study NCT05559801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived mesenchymal stromal cells (MSCs)
Description: Mesenchymal stromal cells (MSCs) are cells of non-hematopoietic stromal origin that reside in bone marrow and a variety of tissues. MSCs will be prepared in a GMP Cell Production facility and administered to children age 3-10 years (at time of enrollment) with Osteogenesis Imperfecta Type III.
Study NCT06297291 — intervention group
Intervention type: DEVICE
Intervention: Paradise Ultrasound Renal Denervation Treatment
Description: The Paradise Ultrasound Renal Denervation System (Paradise Ultrasound RDN) is an FDA-approved catheter-based system to treat hypertension by ablating the nerves around the renal arteries, disrupting the overactive sympathetic nerves that can cause high blood pressure. The Paradise procedure uses ultrasound energy to calm the nerves near the kidneys to help lower blood pressure.~Treatment is usually done in an outpatient setting and typically takes about an hour to perform. As a part of the treatment, a small flexible tube (catheter) is guided into the blood vessels near the kidneys and 7 seconds of ultrasound energy is applied 2-3 times. Both sides are treated and then the catheter is removed, leaving nothing behind. After the procedure, some people go home the same day or some stay overnight.
Study NCT05523622 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Tono-Vera tonometer
Description: The tonometer measures intraocular pressure with a small rebound probe, similar to those used with other tonometers currently on the market, such as the iCare.
Study NCT05523622 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Goldman Applanation Tonometry
Description: This is the current gold standard for measuring eye pressure.
Study NCT04424784 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5% O2
Description: 5% oxygen will be used during oocyte retrieval, fertilization check and embryo grading
Study NCT05989984 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ODF Iron Supplement
Description: ODF iron supplement will be admistered daily for 8 weeks.
Study NCT05989984 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron Supplement in Capsules
Description: Iron supplement in capsule will be admistered daily for 8 weeks.
Study NCT05751512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG003
Description: Administered intravenously
Study NCT05751512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab injection
Description: Administered intravenously
Study NCT05751512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate Injection
Description: Administered intravenously
Study NCT06296095 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell therapy
Description: Subjects were placed sequentially into three different dose groups, 5.0×107 cells/time (low-dose group), 1.5×108 cells/time (medium-dose group), and 5.0×108 cells/time (high-dose group) for dose escalation
Study NCT06362980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-1178
Description: 200 or 300 mg, oral, QD
Study NCT06362980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: 80mg, oral, QD
Study NCT04749589 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: iron deficiency
Description: Its not an intervention. Its an observational study. The groups are defined based on their iron status
Study NCT05672979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab Injection [Beovu]
Description: brolucizumab 6mg intravitreal injection
Study NCT05429970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-body resilience training
Description: MBRT is a meditation technique used to achieve relaxation)
Study NCT05429970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Music listening was found, in multiple trials, to significantly reduce self-reported anxiety, physiologic indicators of anxiety, and/or sedation requirements
Study NCT05429970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol 20 mg PO BID (for 21 consecutive days), Propranolol 10mg PO BID (for 3 consecutive days POD 14-16)
Study NCT05429970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etodolac
Description: Etodolac 400 mg PO BID (for 21 consecutive days)
Study NCT06492694 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil + wild orange essential oil supplement
Description: This supplement contains fish oil and wild orange essential oil as its active ingredients.
Study NCT06492694 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil supplement
Description: This supplement contains fish oil as its active ingredient.
Study NCT05635578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sleep
Description: reiki
Study NCT04984291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alliance Glenoid
Description: Alliance Glenoid used in Primary or Revision Total Shoulder Arthroplasty
Study NCT04984291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Identity Stem
Description: Identity Shoulder System is intended to be used in anatomic total shoulder arthroplasty, shoulder hemi-arthroplasty, or total reverse shoulder arthroplasty in both Primary or Revision Total Shoulder Arthroplasty
Study NCT06572228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dupilumab
Description: Administered by subcutaneous (SC) injection
Study NCT05959382 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Loupe
Description: Magnification aid
Study NCT05959382 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Operation Microscope
Description: Magnification aid
Study NCT04870814 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tactical tourniquet set up
Description: The tactical tourniquet will be set up to the upper limb and the lower limb during a maximum of 2 minutes.
Study NCT06572228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Administered by SC injection
Study NCT06572228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICS/LABA
Description: Administered at a blinded dose
Study NCT06572228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ICS/LABA
Description: Administered at a blinded dose
Study NCT04911751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBL697
Description: 1 capsule BID of KBL697 or Placebo
Study NCT04911751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBL697
Description: 5 capsules BID of KBL697 or Placebo
Study NCT05195073 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopy
Description: 3 D laparoscopy
Study NCT05375474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation therapy
Description: Vitamin-K antagonists (warfarin)
Study NCT05375474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single antiplatelet therapy
Description: Aspirin
Study NCT04870814 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Medical ultrasound
Description: The efficacy of tactical tourniquet set up will be assessed by medical ultrasound.
Study NCT04870814 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: The participants will have to fill a questionnaire assessing pain (for the receiver), ease of use, stability and rusticity (for the fitter).
Study NCT04867395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HELPix Care Plan
Description: A web application tool for CMC - Health literacy-informed, disease and medication-specific, standardized discharge instructions that will: 1) facilitate plain language provider/parent communication at hospital discharge and 2) act as stand-alone handouts that parents can use at home.
Study NCT06384144 — intervention group
Intervention type: OTHER
Intervention: Expectant Management of First Trimester Miscarriage
Description: Expectant Management: Conservative management if miscarriage with follow-up booked in 2 weeks to determine whether complete miscarriage has occurred.
Study NCT06384144 — intervention group
Intervention type: OTHER
Intervention: Medical Management of First Trimester Miscarriage
Description: Medical Management: Misoprostol taken to manage first trimester miscarriage, with follow-up booked in 2 weeks to determine whether complete miscarriage has occurred.
Study NCT05361148 — intervention group
Intervention type: OTHER
Intervention: no interventions will be used
Description: This is a cohort study with no interventions.
Study NCT04922255 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reusable Underwear
Description: Reusable Underwear are similarly available for purchase online and are absorbent underwear for bladder leak protection
Study NCT04922255 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Disposable urethral support
Description: The disposable urethral support is a tampon-like device that is available over the counter to help women with urinary incontinence (UI)
Study NCT04922255 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor physical therapy
Description: Experienced pelvic health physical therapists (at University of Pittsburgh) will complete two visits one week apart.
Study NCT05330364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide 30mg/d p.o. begin at day 1, twice per week, during a 28-days cycle.
Study NCT05330364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Cladribine 5mg/m2/d i.v. d1-5, once per day, during a 28-days cycle.
Study NCT06231758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200mg
Description: Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and help relieve symptoms of arthritis (eg, osteoarthritis, rheumatoid arthritis, or juvenile rheumatoid arthritis), such as inflammation, swelling, stiffness, and joint pain.
Study NCT06231758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin (MET), a traditional antdiabetic drug, exerts glucose-lowering effect by activating AMPK since it is a critical enzyme in lipid and glucose metabolism
Study NCT05638503 — intervention group
Intervention type: OTHER
Intervention: Left ventricular hypertrophy
Description: Hypertension with normal left ventricular geometry and left ventricular concentric remodeling
Study NCT05638503 — intervention group
Intervention type: OTHER
Intervention: Left ventricular non-hypertrophy
Description: Hypertension with left ventricular concentric hypertrophy and left ventricular eccentric hypertrophy
Study NCT05594836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant Calming Training
Description: Perception of Maternal Role, Maternal Attachment and Breastfeeding Self-Efficacy during Infant Calming Training
Study NCT05460442 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caudal Block group
Description: Patients will be placed in the lateral decubitus position. After local sterilization with povidone-iodine, the sacral hiatus will be visualized at the level of the sacral Cornus by ultrasound. The needle will be advanced toward the upper third of the sacrococcygeal ligament. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament. At this level, after confirming the absence of blood or cerebrospinal fluid on aspiration, bupivacaine 0.25% (0.5 mL/kg) will be injected over 1 minute
Study NCT05460442 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group block
Description: Patients will receive ultrasound-guided Pericapsular nerve group block in the supine position after proper sterilization of the groin region. The needle will be inserted in-plane with the transducer. The Pericapsular nerve group block group will receive 0.5 mL/kg of (0.25%) bupivacaine after a negative aspiration
Study NCT05421455 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Group A
Description: treat participants with biologics
Study NCT06148038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD Oral
Description: CBD Oral 350mg twice daily for 28 days
Study NCT06148038 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo Control
Study NCT05421455 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Group B
Description: treat participants with surgery
Study NCT06274814 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: U/S guided Type 2 Pectoral Nerve Block
Description: 20 mL separates the pectoralis major and minor muscles, while 10 mL separates the serratus and pectoralis major muscles
Study NCT06274814 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: U/S guided RIB combined with the sub-serratus plane block (RISS)
Description: he ipsilateral arm was abducted. RISS was performed. Using a 6-13 MHz linear ultrasound probe was placed medial to the medial border of the scapula in the oblique sagittal plane.. A 100-mm 21-gauge needle was inserted at the level of T5-6 in the ultrasound view. A single dose of 20-mL 0.25% bupivacaine was injected in the interfascial plane between the rhomboid major and intercostal muscles. The spread of the local anesthetic solution under the rhomboid muscle was visualized by ultrasonography. Thereafter, the ultrasound probe was moved caudally and laterally to identify the tissue plane between the serratus anterior and external intercostal muscles for the sub-serratus block at the T8-9 level. The needle was advanced from its previous position, and an additional 20 mL of 0.25% bupivacaine was injected.
Study NCT05460442 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascia iliaca group
Description: Patients will receive Ultrasound-Guided fascia iliaca compartment block in the supine position after sterilization of groin area. The needle will be inserted in-plane with the transducer. The needle tip will be advanced through the fascia iliaca and inserted further cephalad just below the fascia iliaca into the iliacus muscle. 0.5 mL/kg of (0.25%) bupivacaine will be injected and visualized moving cephalad away from the needle tip
Study NCT05287880 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamic PET/CT
Description: After transmission CT scan for subsequent PET data attenuation correction, continual dynamic clinical PET scans were performed in a single bed position immediately after 18F-FAPI intravenously injection (210 ± 30 MBq) in list mode for 60 minutes in supine position, dynamic 48 time frames PET/CT imaging was obtained. And then underwent whole body static PET scan.
Study NCT05561322 — intervention group
Intervention type: OTHER
Intervention: Consultation involving pain evaluation, questionnaires and the Lasègue Manoeuver
Description: Raising the lower limb with the knee in extension reproduces sciatica pain if there is an impression of discal pain with its origin at the roots of the sciatica nerve L5 and S1. This test is evaluated by the degree of elevation of the lower limb relative to the examination table. During the Lasègue manoeuvre the sciatica pain is improved during dorsal flexion of the foot.The doctor notes whether the Lasègue manoeuvre done on the healthy side exacerbates the pain on the opposite side. It is said that contralateral Lasègue sign is positive.
Study NCT05561322 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Imaging of the lumbar spine
Description: Sagittal proton density-weighted Dixon sequence on the lumbar spine and axial T2-weighted spin echo sequence on the lumbar discs.
Study NCT05900856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low caloric diet regimen
Description: lipids approximately (20: 35%) of total caloric intake, protein approximately (10: 35%) of total caloric intake and high complexed carbohydrate intake approximately (45: 65%) of total caloric intake (with increased fiber-rich whole grain breads, cereals, fruits and vegetables), for eight weeks.
Study NCT05900856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound cavitation
Description: patients will assume standing position, the abdominal area will be divided vertically into 2 equal sections, right and left segment, extending bilaterally from the line stretching between the mid axilla above and the iliac crest below, and upward from center of diaphragm to the midpoint extending between two iliac crest below, then from supine lying position the cavitation head will be applied on each abdominal segment for 15 minutes with total treatment time 30 minutes twice per week for eight weeks
Study NCT05711862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUVO
Description: Participants will receive 20mg of SUVO for 7 days. Participants will be directed to take the medication between 9:30 PM and 10:00PM.
Study NCT05711862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive 0mg of placebo for 7 days. Participants will be directed to take the medication between 9:30 PM and 10:00PM.
Study NCT04617184 — intervention group
Intervention type: OTHER
Intervention: NO INTERVENTION
Description: THERE IS NO INTERVENTION TO THIS TRIAL. THIS IS A REGISTRY
Study NCT06259422 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Iohexol
Description: Subjects will receive a single bolus of 5 mL of Omnipaque 300 (containing 3235 mg iohexol)